NCT03168854View on ClinicalTrials.gov

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 26, 2017

Primary Completion Date

August 16, 2019

Study Completion Date

August 16, 2019

Conditions
Plasmodium Falciparum Infection
Interventions
BIOLOGICAL

Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain

Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).

OTHER

Malaria challenge

Exposure to mosquitoes infected with P. falciparum.

Trial Locations (1)

98101-1466

Kaiser Permanente Washington Health Research Institute, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03168854 - Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites | Biotech Hunter | Biotech Hunter